Results obtained by Gilead and Arcus could rekindle interest in the anti-TIGIT modality, which has seen many setbacks in the ...

MFN-driven drug price reductions in the US are unlikely to have a big impact pharma R&D spending, experts agree.

Sanofi acquired commercialisation rights for the radiopharmaceutical AlphaMedix from Orana Med in September 2024.

Nanobiotix's JNJ-1900, which is in Phase III for HNSCC, exhibited an ORR of 69% in oesophageal cancer, potentially ...

Cognivia Signal will try to predict which patients are at risk of dropping out to give sponsors the opportunity to intervene.

Takeda will step away from cell therapy in favour of biologics, small molecules and ADCs in a “strategic portfolio prioritisation”.

The VESALIUS-CV trial (NCT03872401) has proved its long-term efficacy in these patients after meeting both its primary ...

The vaccine was generally well tolerated among the paediatric population, with no unexpected safety signals reported. Credit: PeopleImages/Shutterstock.com. Bavarian ...

The trial aims to determine the dosing interval, optimal dose and number of administrations for curing chronic hepatitis B. Credit: Gorodenkoff/Shutterstock.com ...

While overall survival (OS) is the king endpoint in oncology trials, it may be overshadowed by surrogates such as progression-free survival (PFS) and objective response rates (ORR) as outcomes improve ...

Skye Biosciences pipeline obesity drug, nimacimab, has failed to trigger significant weight loss as a monotherapy in a proof-of-concept Phase IIa trial. Image credit: Yellow_man / Shutterstock.com ...

SCYNEXIS has reported encouraging outcomes from a Phase I clinical trial of SCY-247, a second-generation triterpenoid antifungal being developed to treat and prevent invasive fungal infections.